PharmaEssentia
藥華醫藥股份有限公司
PharmaEssentia is a Taiwan TWSE-listed biotechnology company; its most advanced asset is P1101 / BESREMi (Supplemental indication approved, Essential thrombocythemia in adults with inadequate response to hydroxyurea), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| P1101 / BESREMi | — | Supplemental indication approved | Essential thrombocythemia in adults with inadequate response to hydroxyurea | China | 2026-10-15 | Company disclosure |
| P1801 | PD-1 antibody | Phase 1; enrolling by invitation | Advanced Solid Tumors | Taiwan | 2025-07-08 | Trial registry |
| KX01 | — | Phase 1; completed | Psoriasis | — | 2025-07-02 | Trial registry |
Key events
- BESREMi approved by NMPA for adult essential thrombocythemia (company disclosure)
- BESREMi approved by FDA for adult essential thrombocythemia (company disclosure)
- BESREMi approved in Japan for essential thrombocythemia (company disclosure)